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Urothelial carcinoma (UC) causes significant morbidity and remains themost expensive cancer to treat because of the
need for repeated resections and lifelong monitoring for patients with non–muscle-invasive bladder cancer (NMIBC).
Novel therapeutics and stratification approaches are needed to improve the outlook for both NMIBC and muscle-
invasive bladder cancer. We investigated the expression and effects of B Lymphoma Mo-MLV Insertion Region 1
(BMI1) in UC. BMI1 was found to be overexpressed in most UC cell lines and primary tumors by quantitative real-time
polymerase chain reaction and immunohistochemistry. In contrast to some previous reports, no association with
tumor stage or grade was observed in two independent tumor panels. Furthermore, upregulation of BMI1 was
detected in premalignant bladder lesions, suggesting a role early in tumorigenesis. BMI1 is not located within a
common regionof genomic amplification inUC. TheCDKN2A locus (whichencodes thep16 tumor suppressor gene) is
a transcriptional target of BMI1 in some cellular contexts. In UC cell lines and primary tissues, no correlation between
BMI1 and p16 expression was observed. Retroviral-mediated overexpression of BMI1 immortalized normal human
urothelial cells (NHUC) in vitro and was associated with induction of telomerase activity, bypass of senescence, and
repression of differentiation. The effects of BMI1ongene expressionwere identified by expressionmicroarray analysis
of NHUC-BMI1. Metacore analysis of the gene expression profile implicated downstream effects of BMI1 on α4/β1
integrin-mediated adhesion, cytoskeleton remodeling, and CREB1-mediated transcription.
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Worldwide, urothelial carcinoma (UC) is the ninth most common
cancer, with approximately 430,000 new cases diagnosed annually
[1]. UC comprises two major tumor groups with different clinical
behavior and pathogenesis pathways. One group (20%-25% at
diagnosis) is invasive (≥ stage T2). Prognosis for muscle-invasive
bladder cancer (MIBC) is poor, with a continued need for the
development of personalized treatment strategies and identification of
novel therapeutic targets. The second group (N70% at diagnosis) is
composed of non–muscle-invasive bladder cancers (NMIBCs) (stage
Ta or T1), which recur frequently (N70%) but infrequently progress
to muscle invasion [2]. Although survival is good, multifocality,
frequent recurrence, and risk of progression make NMIBC difficult tomanage. Overall, UC is the most expensive cancer to treat because of
the need for lifelong disease monitoring and repeated resections [3].
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will only be possible by achieving a better understanding of the
molecular events involved in the development of UC. Expression of
telomerase is thought to be one of the earliest steps in tumorigenesis
because it can be detected in premalignant lesions [4,5]. During
modeling of the early events in UC tumorigenesis in vitro, B
Lymphoma Mo-MLV Insertion Region 1 (BMI1) was found to be
overexpressed in genetically normal, telomerase-immortalized normal
human urothelial cells (TERT-NHUC) compared with isogenic
mortal NHUC [6]. BMI1 (10p11.23) encodes a key component of
polycomb repressive complex 1 (PRC1). The protein contains a
conserved RING finger domain and a central helix-turn-helix motif
[7]. Although it is not enzymatically active itself, as part of PRC1,
BMI1 is involved in the regulation of the transcription of many genes
relevant to cancer and development [8]. In some but not all tissues,
BMI1 is thought to promote tumorigenesis, in part, by silencing of
the CDKN2A locus, which encodes the tumor suppressor gene p16
[9]. However, in the Ewing sarcoma family of tumors, BMI1
promotes the tumorigenicity of both p16 wild-type and p16-null cell
lines, indicating that, in some cell types, the role of BMI1 in
oncogenesis can be p16 independent [10]. BMI1 also contributes to
tumorigenesis in an ink4a/arf-deficient mouse model of glioma [11],
strongly implicating other BMI1-associated pathways in cancer. The
relationship between BMI1 and the CDKN2A locus in urothelial cells
is unknown. The effects of BMI1 on gene expression or phenotype
are also not understood in this cell type, although since our study was
initiated, effects on proliferation and migration of the T24 UC cell
line have been reported by Liang et al. [12].
Here, we examined expression of BMI1 transcript in a large panel
of UC cell lines and primary tumors and used immunohistochemical
detection in two independent primary UC tumor panels and samples
of potentially premalignant urothelium. Using stable retroviral-
mediated transduction, we investigated the phenotypic effects of
BMI1 overexpression in NHUC and UC cell lines in vitro. Gene
expression analysis of BMI1-immortalized cells (NHUC-BMI1)
identified consistent downstream changes in gene expression and
novel associations with key signaling pathways. Therapeutic
inhibition of BMI1 is showing promise in colorectal cancer [13].
Therefore, a better understanding of the contribution of BMI1
upregulation to bladder tumorigenesis will provide rationale and insight
into targeting this key molecule and associated pathways in UC.
Materials and Methods
Cell Lines and Tissue Samples
UC cell lines and NHUC were cultured and cell line identity was
verified as described previously [14]. NHUC are cultured on Primaria
cell culture dishes or flasks (Corning). Tissue was obtained with
written patient consent and the approval of the Local Research Ethics
Committee from patients at St. James's University Hospital, Leeds,
UK. In a panel of 71 tumors, there were 6 pTaG1, 26 pTa G2, 3 pTa
G3, 6 pT1G2, 14 pT1 G3, 7 T2 G3, 3 pT3 G3, 4 pTxG2, and 2
pTxG3. For 14 cases, both initial and subsequent tumors were
available for the same patient. A second tissue tumor microarray
(TMA) panel was obtained from 93 UC patients at Hospital
Guadalajara and Hospital Central de Asturias, Spain, as described
previously [14]. Tumors were graded according to the 1973 WHO
recommendations and staged according to tumor–node–metastasis
classification. Clinicopathological data were collected from patientnotes after completion of laboratory analyses a minimum of 3 years
after collection of the initial sample. Samples of primary UC for
quantitative real-time PCR (QRTPCR) have been described [15].
Tumor information is listed in Supplementary Data. Additional
information towards meeting the reccomendations of the REMARK
guidelines (REporting recommendations for tumor MARKer prog-
nostic studies) [16] is included in Supplementary Information.
Quantitative Real-Time Polymerase Chain
Reaction (QRTPCR)
QRTPCR was performed on 23 UC cell lines and 59 primary UC
using Taqman assay on demand; BMI1 (Hs00180411_m1) (Life
Technologies, Paisley, U.K). Expression was quantified relative to
SDHA control (Hs00417200_m1) and normalized to pooled cDNA
from NHUC. Reactions were performed in triplicate, and each plate
contained a no template control.
Immunohistochemistry
For detection of BMI1, primary antibody was mouse anti-BMI1
(clone F6, Millipore). For antigen retrieval, slides were pressure
cooked for 2 minutes at full pressure with 0.1 M citric acid buffer (pH
6). Positive controls were normal tonsil or placenta. Baseline
expression was defined by normal urothelium in each batch of
tumors or TMA. To prepare control cell pellets, cells were harvested
with 0.1% EDTA/PBS and 0.05% Trypsin/EDTA, pelleted by
centrifugation, fixed overnight in 4% formalin, and then transferred
to 70% ethanol. Approximately 1-cm3 wells were formed using
tinfoil spread over and slightly compressed into a laboratory rack.
Pellets were transferred to these wells, agarose at 45°C was added to
cover the pellet, agarose was allowed to set, and the agarose-enclosed
cell pellet was refixed in formalin before embedding in paraffin wax.
BMI1 expression in UC was homogeneous and nuclear. Expression
was scored as follows: 0: absent or weak staining in b50% urothelial
nuclei, 1: weak staining in N50% or moderate staining in b50%
nuclei, 2: moderate staining in N50% nuclei, or 3: strong staining
in N50% nuclei. A score of 0 or 1 was deemed low expression and
comparable to normal expression. A score of 2 or 3 was deemed to be
overexpression relative to normal bladder urothelium. Sections were
scored independently by E.C., J.R., and M.K., and any discrepancies
between low or overexpression were resolved. For detection of p16,
5-μm deparaffinized and rehydrated sections were treated with 3%
hydrogen peroxide (Sigma Aldrich, Poole, UK), Avidin Biotin
blocking kit (Vector Laboratories, Peterborough, UK), and catalyzed
signal amplification system (DakoCytomation, Buckinghamshire,
UK). Primary antibody was mouse anti-p16 (Ab-7; Labvision,
Suffolk, UK). Slides were counterstained with hematoxylin, dehy-
drated, and mounted. Positive control for p16 expression was cervical
carcinoma. p16 was scored as negative, heterogeneous, or strong
expression in N50% of tumor cells as described [17].
Retroviral-Mediated Transduction
Retroviral transduction was performed as described previously
[18]. For stable BMI1 knockdown, plasmids were kindly provided by
Elizabeth Lawlor [10]. siBMI1-A and siBMI1-B DNA oligonucleotide
sequences (siBMI1-A, 5'-CCGUCUUAAUUUUCCAUUG-3'; or
siBMI1-B, 5'-GCGGUAACCACCAAUCUUC-3') were cloned into
the pSuper-retro-puro short-hairpin vector backbone (shBMI1-A
and shBMI1-B; Oligoengine). A nonsilencing sequence with
no significant homology to any mammalian gene sequence
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negative control [10]. pBabe-BMI1 for ectopic overexpression
of BMI1 was a kind gift from Goberdhan Dimri and resulted
in overexpression within the range of endogenous overexpression
observed in primary UC.
Phenotypic Assays
Cells expressing senescence-associated β galactosidase were detect-
ed using the senescent cells histochemical staining kit (Sigma, Poole,
UK). At 200× magnification, total and stained cells were counted
within a 1-mm2 area. Three unselected areas were counted in each of
triplicate wells. For measurement of cumulative population dou-
blings, cells were seeded at 3 × 104 cells per 9.6-cm2 well in triplicate
and passaged before confluence. Growth kinetics were examined
during the log phase of growth. Anoikis, anchorage-independent
colony formation, and induction of differentiation were assessed as
described previously [14,19]. For assessment of adhesive capacity, 3 ×
104 cells were seeded under standard conditions. After 30 minutes,
adherent cells were trypsinized and counted. To assess migration,
7.5 × 104 cells in unsupplemented medium were seeded onto
triplicate 4.67-cm2, 0.8-μm–pore Transwells with complete growth
medium below the Transwell (BD Biosciences, Oxford, U.K). After
48 hours, Transwells were fixed in methanol:acetone. Cells that had
transversed the membrane were stained with diamidino-2-phenylindole
and visualized at ×4. Images were recorded from four unselected areas of
each Transwell, and cell number was scored using ImageJ particle
analysis (imagej.nih.gov).
Telomerase Activity
Telomerase activity was quantified using the TRAPEZE XL
Telomerase detection kit (Millipore, Watford, UK). Sample cell
pellets and the control pellet provided with the kit were prepared from
1 × 106 cells and lysed with 200 μl of CHAPS. Protein content of
lysates was determined using the Biorad protein assay (Biorad, Hemel
Hempstead, UK), and samples were diluted to 1 μg of protein in 2 μl
of CHAPS. Samples were assayed in triplicate, and an aliquot of the
sample was heat inactivated at 70°C as a negative control. Cycling
conditions were as follows: 30°C for 30 minutes, 95°C for 2 minutes,
followed by 45 cycles of 94°C for 15 seconds, 59°C for 1 minute, and
45°C for 35 seconds. Quantification was performed using an ABI
PRISM 7500 Sequence detector.
Next-Generation Sequencing (NGS) for Copy Number Analysis
Libraries were prepared for sequencing using NEB NGS library
preparation kits with custom tags in an updated version of methods
found in Wood et al. (2010) [20]. Samples were pooled onto an
Illumina HiSeq2500 for 2× 101-bp sequencing. Sequence was
trimmed to remove adapters using cutadapt [21] and then aligned to
the human genome hg19 using Burrows-Wheeler alignment tool
[22]. Copy number was calculated by splitting the genome into
equal-sized windows with an average of 400 reads per window and
comparing ratio of tumor and normal samples, and plots were
produced using CNAnorm [23] with breakpoints called using
DNAcopy [24]. NHUC-BMI1 samples were compared with isogenic
mock or vector transduced cells.
Expression Array Analysis
Gene expression analysis was performed using Affymetrix
HG_U133 PLUS 2.0 arrays as described previously [6]. Data wereanalyzed using Partek Genomics Suite 6.5 (Partek Inc., Missouri,
USA). Genes differentially expressed in BMI1-transduced NHUC
(NHUC-BMI1) compared with isogenic NHUC were identified
using a two-sample t test. Genes consistently altered by at least
two-fold in cells from both donors were identified (P b .05 and Q
false discovery rate b 0.1). This gene list was input into Metacore
(www.http://thomsonreuters.com/metacore/ for further analysis.
Results
Up-Regulation of BMI1 Transcript in UC Cell Lines
and Primary Tumors
An initial screen of BMI1 expression by QRTPCR found
overexpression in 9/23 (39%) UC cell lines (Figure 1A) and 55/57
(96%) of primary UC relative to NHUC (Figure 1B). There was no
association between BMI1 transcript level and stage or grade in these
primary tumors. Gene expression array analysis of UC cell lines
(Hurst et al., manuscript in preparation) demonstrated that there was
a slight positive correlation (P = .0146, r = 0.3617) between BMI1
and p16 transcript expression. This indicates concurrent expression of
BMI1 and p16 rather than the negative correlation that would
indicate BMI1-mediated repression of CDKN2A transcription
(Figure 1C). BMI1 at 10p11.23 is not in a region commonly
amplified in UC [25], and examination of copy number data for our
UC cell line panel (unpublished data) confirmed that upregulation of
BMI1 transcript expression was not due to genetic amplification or
duplication in this region. Furthermore, analysis of cBioportal data
confirmed a b2% rate of genetic amplification of BMI1 in bladder cancer
and b5% in other tumor types analyzed (http://www.cbioportal.org).BMI1 Protein Expression
Having observed common upregulation of BMI1 transcript in
UC and UC cell lines, we investigated protein expression in primary
UC. Normal tonsil showed nuclear positivity in germinal regions as
described previously [26] (Supplementary Figure 1A). An additional
positive control was human placenta (Supplementary Figure 1B).
No primary antibody negative controls showed no staining
(Supplementary Figure 1C), and in normal urothelium, BMI1
expression was absent, or nuclear and weak (Supplementary Figure 1,
D and E). Additional controls were pellets of cultured cells with
known BMI1 transcript expression; NHUC, low expression
(Supplementary Figure 1F) or TERT-NHUC, high expression
(Supplementary Figure 1G). Sections were scored for BMI1
expression on a 4-point scale as described in Materials and Methods
(Supplementary Figure 1, H–K). As BMI1 is reported to inhibit
expression from the CDKN2A locus, sections of the same tumor
block or TMA were stained for both p16 and BMI1 expression to
investigate the relationship between these two proteins. Individual
tumors with high BMI1 expression and loss of p16 expression
(Figure 2, A and B) or loss of BMI coupled to high p16 expression
(Figure 2, C and D) were observed. Coexpression of high levels of
both proteins was also seen (Figure 2, E–H). In the initial tumor
panel (comprising 71 tumors from 54 patients), 63/71 (89%) tumors
had overexpression of BMI1 relative to normal urothelium. No
correlation with tumor grade or stage was seen. High BMI1
expression could be detected in noninvasive, stage pTa tumors
(Figure 2G) or muscle-invasive, pT2 tumors (Figure 2E). Only eight
tumors in this panel had low or no BMI1 expression. These were
TaG1 (1 case), TaG2 (1 case), T1G2 (1 case), T1G3 (1 case), and
Figure 1. (A) Overexpression of BMI1 in UC tumor cell line panel as detected by QRTPCR. Expression is normalized to NHUC. Cell lines
from left to right are as follows: RT112M, 97-1, BFTC905, TCCSUP, SD, T24, SCaBER, CAL29, 253J, HT1376, DSH1, 5637, RT4, 97-24,
VMCUB3, SW1710, BFTC909, KU1919, JON, 97-7, 96-1, 94-10, and LUCC1. (B) Expression of BMI1 in a primary UC panel. Tumor
information is given in supplementary data. (C) Expression array analysis showed a slight positive correlation between BMI1 and p16
transcript in UC cell lines in contrast to the theory that BMI1 is a transcriptional repressor of the CDKN2A locus in this cell type. Expression
is shown relative to pooled NHUC.
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tumor in the panel. In 13 of these, the initial and recurrent tumor
both had high expression of BMI1. In one case, BMI1 was low in the
earlier tumor but upregulated in the later recurrence, and in two cases,
it was high in the first presentation but low in the recurrence.
Twenty-nine of 71 (40%) tumors in this panel had loss of p16
expression, which is concordant with the rate of homozygous deletion
of the CDKN2A locus that we previously described in UC [17].
Twenty-eight of 71 (39%) cases showed coexpression of high levels of
BMI1 and p16.
Common overexpression of BMI1 in UC was confirmed in an
independent TMA panel comprising 28 pTaG1, 8 pTaG2, 4 pTaG3,
1 pTaGx, 5 pT1G2, 19 pT1G3, 19 pT2G3, 1 pT2Gx, 3 pT3G3, 1
pT3Gx, 4 pT4G3, and 1 pT4Gx. In this panel, 89/94 (95%) of
tumors had overexpression of BMI1, and again there was no
association between overexpression and tumor stage or grade
(chi-square test, P ≥ .05). Tumors of unknown grade or stage were
not included in this analysis. Loss of p16 expression was observed in
43/94 (46%). Fifteen of 94 cases (16%) exhibited strong coexpression
of p16 and BMI1, again indicating no significant transcriptional
repression of the CDKN2A locus.
Expression of BMI1 in Premalignant Bladder Lesions
and Carcinoma In Situ (CIS)
The observation that upregulation of BMI1 in UC was not
associated with stage or grade indicates that it may be an early event in
UC tumorigenesis. We hypothesized that, if this was the case,
upregulation of BMI1 expression would also be detected in
premalignant bladder lesions. We stained sections from the non–
tumor-associated regions of the bladder in cystectomy specimens (n =
6) and noncancerous lesions that were detected at check cystoscopy in
patients previously diagnosed with UC (n = 12). Upregulation of
BMI1 was detected in examples of CIS (Figure 2, I and J), chronic
inflammation (in the absence or presence of CIS), and urothelium
reported to show no evidence of malignancy (Supplementary
Information 1). Areas of urothelium distant from the tumor in
cystectomy specimens showed upregulation of BMI1 in CIS but notnormal urothelium. In one case, upregulated BMI1 expression was
seen in CIS but not in the adjacent normal urothelium, delineating
the margin of CIS (Figure 2K).
Immortalizing Effects of Ectopic Overexpression of BMI1
To investigate the role of BMI1 in urothelial tumorigenesis, retroviral
transduction was used to stably overexpress BMI1 in NHUC. The resulting
NHUC-BMI1 showed a bypass of replicative senescence, as determined by a
lack of elevation of senescence-associated β galactosidase expression
(Figure 3A). Ectopic expression of BMI1 appeared to immortalize NHUC
from two initial donors (A and N) in a single step. Cells proliferated
continuously for over 100 days (Figure 3B). Immortalization was then
confirmed usingNHUC from a third donor (803). NHUC-BMI1 cell lines
did not exhibit anchorage-independent growth (data not shown).
Characterization of NHUC-BMI1
Using NGS for copy number analysis, between 2.4 and 4.7 million
read pairs were produced per sample, equating to between 480 and 950
Mb of sequence or 0.16 to 0.32X coverage of the human genome. No
copy number alterations were detected in NHUC-BMI1 from donors
N and 803, but gains on chromosome 20 and 9q were found in
NHUC-BMI1 from donor A (Supplementary Figure 2). Interestingly,
an hTERT immortalized NHUC (TERT-NHUC) cell line previously
derived from the same donor contained an abnormal clone with an
unbalanced rearrangement of 20q (46,XY, add (20)(q12)) that resulted
in partial loss of 20q and gain of unidentified material [18], suggesting a
donor-specific effect rather than an event necessary for immortalization.
Telomerase activity was greater in NHUC-BMI1 relative to empty
vector transduced cells (Figure 3C). Previously, we have shown that
NHUC immortalized by hTERT exhibit a reduced differentiation
capacity [27]. Here, we found that induction of uroplakin 2, amarker of
urothelial differentiation, was also repressed inNHUC immortalized by
BMI1 compared with empty vector-transduced controls (Figure 3D).
Gene Expression Profile of NHUC-BMI1
Expression array analysis revealed at least two-fold changes in
expression of 2614 probes (1050 genes) in NHUC-BMI1 relative to
Figure 2. Examples of immunohistochemistry on formalin-fixed, paraffin-embedded human tissues or cell pellets. Panels (A–H) are shown
at 200× magnification; (I–K), 100×. (A) UC BMI1 score 3; (B) same UC, p16 negative; (C) UC, BMI1, score 0; (D) same UC, p16 strong;
(E) UC, BMI1, score 3; (F) same UC, p16 strong; (G) UC, BMI1 score 3; (H) same UC, p16 strong; (I) CIS, BMI1, score 3; (J) CIS, BMI1, score
2; (K) CIS, BMI1, score 2. Arrow highlights border of normal urothelium and CIS.
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(Supplementary Data 1). Transcription of the CDKN2A gene was
not downregulated in NHUC-BMI1 as confirmed by QRTPCR
(Figure 3E). Metacore enrichment analysis was used to examine how
enriched the data set (Supplementary Data 1) is in a particular map or
network within the program, taking into account the number of
objects in the gene list, the number of objects in the map/network,
and the number of objects within the entire Metacore database. Gene
ontology processes, process networks, and diseases most overrepre-
sented in the data set are shown in Supplementary Data 1. The top 30
upregulated and downregulated probes are shown in Table 1, and the
top 30 overconnected genes are shown in Table 2. Reassuringly, thisanalysis highlighted known functions of BMI1. The top process
network was mRNA processing, and the top 7 disease-associated
biomarkers identified were consistent with the known association of
BMI1 upregulation in colorectal cancer.
Meng et al. previously performed genomewide mapping of
targets of BMI1 in the epithelial HeLa tumor cell line using
chromatin immunoprecipitation [28]. To identify true BMI1-
mediated changes in gene expression, we overlaid the NHUC-BMI1
data set with the data set of Meng et al. There was an overlap of 88
genes (Table 4), which could be arranged into three networks
(Supplementary Figure 3). The first and second networks both
showed involvement of CREB transcriptional targets. Of note, there
Figure 3. (A) Overexpression of BMI1 led to a bypass of senescence in NHUC. Filled bars show senescence-associated β-galactosidase
expression in empty vector-transduced NHUC; and unfilled bars, BMI1-transduced cells. (B) Ectopic expression of BMI1 led to
exponential growth of the cell population and apparent immortalization in cells from three independent donors. Filled symbol shows
vector-transduced cells; and unfilled symbols, NHUC-BMI1. (C) Detection of telomerase activity in NHUC-BMI1 using quantitative
real-time PCR-based method. HI represents heat-inactivated sample, No Taq is a no polymerase negative control, and positive control is a
lysate of the control pellet from the TRAPEZE XL kit. (D) Overexpression of BMI1 repressed induction of differentiation in NHUC. Induction
of uroplakin 2 (UPK2), a marker of urothelial differentiation, was repressed in NHUC-BMI1 compared with vector control cells after
treatment with trogiltazone and EGFR inhibitor. Expression is normalized to NHUC-vector control treatment cells. (E) Quantitative
real-time PCR confirmed that overexpression of BMI1 did not repress CDKN2A transcription in NHUC. Expression was quantified relative
to pooled cultured NHUC.
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Table 1. Top 30 Upregulated and Downregulated Probes in Affymetrix Expression Array Analysis
Top 30 upregulated probes in NHUC-BMI1 relative to isogenic NHUC-vector
Donor 1 Donor 2 Average
Probeset ID Gene Symbol Fold
Change
P Value Fold
Change
P Value Fold
Change
202237_at NNMT 176.00 4.48E-05 24.92 2.19E-03 100.46
202238_s_at NNMT 51.50 9.67E-06 21.41 8.08E-04 36.46
209949_at NCF2 4.30 3.51E-02 24.66 1.64E-03 14.48
210809_s_at POSTN 3.08 1.30E-01 25.74 3.76E-02 14.41
1560679_at LOC151438 21.13 5.02E-03 3.30 3.89E-01 12.22
225911_at NPNT 9.85 2.32E-04 13.28 1.58E-03 11.56
209351_at KRT14 14.65 5.71E-03 7.83 5.77E-02 11.24
201141_at GPNMB 2.05 4.97E-01 19.30 7.32E-02 10.68
219630_at PDZK1IP1 14.47 3.31E-05 6.83 1.35E-02 10.65
206912_at FOXE1 12.95 1.69E-05 6.84 4.51E-04 9.89
232861_at PDP2 9.89 1.77E-04 9.12 3.35E-04 9.51
220014_at PRR16 13.05 4.97E-05 5.76 2.78E-02 9.41
224823_at MYLK 6.94 3.05E-03 11.64 9.66E-04 9.29
244780_at SGPP2 2.80 1.11E-01 14.98 5.54E-02 8.89
231331_at – 11.28 2.45E-05 5.34 7.21E-04 8.31
202766_s_at FBN1 2.91 6.49E-03 13.49 7.69E-04 8.20
1553589_a_at PDZK1IP1 10.11 3.39E-04 6.09 8.71E-03 8.10
1556499_s_at COL1A1 5.76 1.56E-03 10.06 2.03E-03 7.91
214701_s_at FN1 12.13 1.22E-03 3.65 5.85E-02 7.89
228854_at – 3.43 1.77E-01 11.77 3.31E-02 7.60
219911_s_at SLCO4A1 8.13 1.27E-03 6.36 2.92E-03 7.25
213040_s_at NPTXR 4.06 1.57E-02 9.89 6.24E-04 6.98
236044_at PPAPDC1A 5.46 5.68E-03 8.32 3.46E-04 6.89
211478_s_at DPP4 4.93 6.20E-04 8.53 2.31E-03 6.73
226388_at TCEA3 6.40 4.22E-03 6.88 9.70E-04 6.64
205547_s_at TAGLN 2.34 2.51E-01 10.62 1.73E-02 6.48
226281_at DNER 2.12 3.72E-02 10.68 9.26E-03 6.40
213385_at CHN2 5.16 3.75E-03 7.62 4.38E-03 6.39
AFFX-DapX-5_at – 7.40 4.89E-04 5.33 1.21E-03 6.37
1555724_s_at TAGLN 2.18 2.51E-01 9.85 1.09E-02 6.01
Top 30 downregulated probes in NHUC-BMI1 relative to isogenic NHUC-vector
Donor 1 Donor 2 Average
Probeset ID Gene Symbol Fold
Change
P Value Fold
Change
P Value Fold
Change
233011_at ANXA1 −19.86 5.33E-03 −47.91 5.49E-04 −33.88
202265_at BMI1* −26.36 1.79E-05 −41.21 2.76E-06 −33.79*
244026_at – −42.42 1.47E-04 −34.65 1.84E-04 −38.54
232113_at – −18.18 6.90E-03 −31.34 1.13E-03 −24.76
232541_at – −21.04 2.31E-04 −30.72 2.24E-04 −25.88
224567_x_at MALAT1 −25.83 1.55E-03 −25.61 2.05E-03 −25.72
226675_s_at MALAT1 −34.50 1.01E-03 −24.15 1.68E-03 −29.33
1558678_s_at MALAT1 −39.70 2.94E-04 −23.55 1.16E-03 −31.62
240815_at – −13.81 4.12E-05 −21.98 2.29E-04 −17.90
209550_at NDN −4.62 5.67E-04 −21.65 4.71E-05 −13.13
227062_at NCRNA00084 −19.22 8.02E-03 −21.58 1.97E-02 −20.40
219795_at SLC6A14 −5.89 2.17E-02 −20.82 4.19E-06 −13.36
224559_at MALAT1 −20.19 3.59E-04 −20.51 2.38E-03 −20.35
235592_at – −11.66 1.44E-03 −20.30 1.02E-05 −15.98
240038_at – −16.43 2.64E-05 −20.01 2.65E-05 −18.22
205513_at TCN1 −17.30 1.34E-03 −19.98 7.03E-05 −18.64
217523_at CD44 −14.96 1.19E-03 −19.86 4.83E-04 −17.41
236879_at – −23.07 8.36E-06 −19.48 2.27E-05 −21.28
236545_at – −9.68 8.53E-04 −19.12 6.65E-05 −14.40
233300_at – −12.36 4.85E-04 −18.34 5.70E-05 −15.35
220940_at ANKRD36B −14.52 6.40E-06 −17.71 3.15E-06 −16.12
231929_at IKZF2 −11.76 7.49E-03 −17.55 8.09E-05 −14.66
242476_at – −12.15 2.13E-05 −17.37 9.94E-05 −14.76
230746_s_at – −2.17 2.12E-01 −16.38 7.62E-03 −9.28
228483_s_at TAF9B −3.51 2.93E-03 −16.08 1.27E-03 −9.79
244741_s_at MGC9913 −4.71 5.82E-04 −15.78 3.08E-04 −10.24
236322_at – −22.66 4.14E-03 −15.54 1.15E-03 −19.10
230229_at DLG1 −11.57 2.47E-04 −15.47 1.38E-04 −13.52
235879_at MBNL1 −15.59 2.12E-05 −15.08 1.58E-04 −15.33
235138_at – −17.81 1.69E-04 −14.98 2.68E-04 −16.39
Fold change is expression in NHUC-BMI1 relative to the isogenic, empty vector transduced
NHUC.
* Endogenous BMI1 was downregulated in NHUC-BMI1. Retroviral-transduced BMI1 was not detected
by the probe because it is located in the 3’ UTR not expressed from the retroviral vector.
Table 2. Top 30 Overconnected Objects
Object Type Network
Object Name
Actual R Expected Ratio p Value z-Score
Transcription factors YY1 255 2891 113.7 2.242 3.689E-37 14.37
Other ELAVL1 (HuR) 205 2042 80.32 2.552 4.018E-37 14.81
Other SUMO-2 145 1339 52.67 2.753 2.881E-29 13.34
Other SUMO-1 125 1102 43.35 2.884 4.777E-27 12.94
Transcription factors CREB1 352 5302 208.5 1.688 5.774E-27 11.41
Transcription factors c-Myc 227 2941 115.7 1.962 2.056E-24 11.24
Enzymes Sirtuin7 87 661 26 3.346 2.851E-23 12.37
Other 14-3-3 zeta/delta 102 984 38.7 2.635 2.901E-19 10.59
Transcription factors p53 141 1774 69.78 2.021 5.539E-16 9.022
Other Cullin 3 97 1095 43.07 2.252 5.824E-14 8.572
Enzymes E2I 49 380 14.95 3.278 2.913E-13 9.055
Other CNOT3 101 1209 47.55 2.124 6.369E-13 8.104
Other SF3A2 27 128 5.035 5.363 6.837E-13 10.01
Other miR-155-5p 40 274 10.78 3.711 8.527E-13 9.131
Kinases PLK1 92 1063 41.81 2.2 1.031E-12 8.091
Transcription factors TARDBP 54 463 18.21 2.965 1.071E-12 8.636
Other FUS 37 240 9.44 3.919 1.149E-12 9.195
Other p15(PAF) 76 808 31.78 2.391 1.99E-12 8.134
Other SUMO-3 57 515 20.26 2.814 2.193E-12 8.416
Other 14-3-3 gamma 57 523 20.57 2.771 4.113E-12 8.281
Transcription factors Oct-3/4 114 1489 58.57 1.946 5.58E-12 7.619
Other U2AF-65 27 146 5.743 4.702 1.792E-11 9.076
Transcription factors ESR1 (nuclear) 137 1966 77.33 1.772 2.851E-11 7.21
Other TIF1-beta 122 1681 66.12 1.845 3.139E-11 7.258
Transcription factors YB-1 46 393 15.46 2.976 4.601E-11 7.988
Other miR-93-5p 24 122 4.799 5.001 6.132E-11 8.964
Kinases CDK9 40 314 12.35 3.239 6.559E-11 8.077
Proteases Caspase-3 57 561 22.07 2.583 6.703E-11 7.673
Other hnRNP A1 44 373 14.67 2.999 9.442E-11 7.87
Other TIP120A 61 634 24.94 2.446 1.319E-10 7.462
There were 990 objects identified in the NHUC-BMI1 data set that were eligible for this analysis
which were analyzed based upon the 25,169 gene-based objects present in the complete database.
Key: Actual is the number of network objects in the BMI1-NHUC data set which interact with the
chosen object, R = number of objects in the complete Metacore database which interact with the
chosen object, Expected is mean value for hypergeometric distribution (n*R/N), Ratio is
connectivity ratio (actual/expected), P value is the probability to have the given value of actual or
higher (or lower for negative z-score), z-score is ((actual − expected)/sqrt(variance)).
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overexpression of CREB1 targets. The top process network identified
was cytoskeleton-actin filaments, and the top pathway map further
implicated overexpression of BMI1 in altered phosphorylation events
and subsequent effects on cytoskeleton remodeling (Figure 4). For
example, NHUC-BMI1 exhibited overexpression of ROCK2 kinase.
This upregulation is expected to impact on downstream actin-
and tubulin-mediated cytoskeleton remodeling and subsequent
cellular migration.
Phenotypic Effects of BMI1 Expression
Analysis of the NHUC-BMI1 gene list by protein function
(Table 3) identified the key pathway map enriched in NHUC-BMI1
expression profile as “cytoskeleton remodeling_Role of PKA in
cytoskeleton reorganisation” (Figure 4A). NHUC-BMI1 had down-
regulation of PKA-cat, a protein responsible for the phosphorylation
and deactivation of α4/β1 integrin, a key molecule in cell adhesion.
Downregulation of the deactivator of α4/β1 integrin would be
expected to result in an increase in cellular adhesion. Indeed,
overexpression of BMI1 in NHUC promoted adhesion under standard
culture conditions (Figure 4B). Analysis of the overlap with theMeng et
al. data set indicated that effects of BMI1 overexpression would include
ROCK-mediated modulation of the cytoskeleton. Accordingly,
NHUC-BMI1 had increased cellular motility as measured by Transwell
migration (Figure 4C). Retroviral-mediated transduction was then
used to stably downregulate BMI1 expression in the UC cell line 97-7.
Table 3. BMI1-Target Genes (Identified by Meng et al., 2010) Whose Expression Was Consistently Altered in NHUC-BMI1 Compared with NHUC
AIG1 Androgen-induced gene 1 protein KLHL42 Kelch-like protein 42 RPS6KA2 Ribosomal protein S6 kinase alpha-2
ALOXE3 Hydroperoxide isomerase ALOXE3 KMT2E Histone-lysine N-methyltransferase 2E RUFY2 RUN and FYVE domain-containing protein
2
AP4E1 Adaptor-Related Protein Complex 4,
Epsilon 1 Subunit
LMLN Leishmanolysin-like peptidase SEC14L1 SEC14-like protein 1
ARHGEF10 Rho guanine nucleotide exchange factor 10 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial SEC62 Translocation protein SEC62
ASXL1 Putative Polycomb group protein ASXL1 MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 SEPT7 Septin-7
BAZ2B Bromodomain adjacent to zinc finger
domain protein 2B
MBOAT2 Lysophospholipid acyltransferase 2 SKA2 Spindle and kinetochore-associated protein 2
BIRC6 Baculoviral IAP repeat-containing
protein 6
MIPOL1 Mirror-image polydactyly gene 1 protein SOX6 Transcription factor SOX-6
CAMTA1 Calmodulin-binding
transcription activator 1
MKLN1 Muskelin SRGAP2 SLIT-ROBO Rho
GTPase-activating protein 2
CDK6 Cyclin-dependent kinase 6 MRPS10 28S ribosomal protein S10, mitochondrial SRRM2 Serine/arginine repetitive matrix protein 2
CFI Complement factor I MSI2 RNA-binding protein Musashi homolog 2 STAM2 Signal transducing adapter molecule 2
CLOCK Circadian locomoter output cycles protein
kaput
MTDH Protein LYRIC SUGCT Succinate-hydroxymethylglutarate
CoA-transferase
CUX1 Homeobox protein cut-like 1 NBN Artemin (ARTN) SULF2 Extracellular sulfatase Sulf-2
DIP2A Disco-interacting protein 2 homolog A NBPF1 Neuroblastoma breakpoint family member 1 TACC2 Transforming acidic coiled-coil-containing
protein 2
DST Dystonin NIN Ninein TC2N Tandem C2 domains nuclear protein
DYNC2H1 Cytoplasmic dynein 2 heavy chain 1 NT5C2 Cytosolic purine 5'-nucleotidase TCF12 Transcription factor 12
EHBP1 EH domain-binding protein 1 PAPOLA Poly(A) polymerase alpha THOC2 THO complex subunit 2
FAM120A Constitutive coactivator of
PPAR-gamma-like protein 1
PGGT1B Geranylgeranyl transferase type-1 subunit beta TMED10 Transmembrane emp24 domain-containing
protein 10
FAM83F Protein FAM83F PIAS1 E3 SUMO-protein ligase PIAS1 TNS1 Tensin-1
FBN1 Fibrillin-1 PMS1 PMS1 protein homolog 1 TPRG1 Tumor protein p63-regulated gene 1 protein
FBXO9 F-box only protein 9 PPAPDC1A Phosphatidate phosphatase PPAPDC1A TRIM33 E3 ubiquitin-protein ligase TRIM33
FGD6 FYVE, RhoGEF and PH
domain-containing protein 6
PPM1D Protein phosphatase 1D UFL1 E3 UFM1-protein ligase 1
FKBP5 Peptidyl-prolyl cis-trans isomerase FKBP5 PPP2R2C Serine/threonine-protein phosphatase 2A 55 kDa regulatory
subunit B gamma isoform
USP34 Ubiquitin carboxyl-terminal hydrolase 34
FOXA1 Hepatocyte nuclear factor 3-alpha PSMD14 26S proteasome non-ATPase regulatory subunit 14 UTRN Utrophin
FRMD4A FERM domain-containing protein 4A PSMG1 Proteasome assembly chaperone 1 VMP1 Vacuole membrane protein 1
GOLGA8B Golgin subfamily A member 8B QPCT Glutaminyl-peptide cyclotransferase VPS13B Vacuolar protein sorting-associated protein
13B
GPD2 Glycerol-3-phosphate dehydrogenase,
mitochondrial
RAB18 Ras-related protein Rab-18 VTA1 Vacuolar protein sorting-associated protein
VTA1 homolog
GRB10 Growth factor receptor-bound protein 10 RAB3GAP2 Rab3 GTPase-activating protein non-catalytic subunit WBSCR27 Williams-Beuren syndrome chromosomal
region 27 protein
H2AFY Core histone macro-H2A.1 RASAL1 RasGAP-activating-like protein 1 ZMYND8 Protein kinase C-binding protein 1
IFT80 Intraflagellar transport protein 80 homolog RNF213 E3 ubiquitin-protein ligase RNF213
KLHL28 Kelch-like protein 28 ROCK2 Rho-associated protein kinase 2
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that is considered functionally inactivated as it is coupled to hyperpho-
sphorylated Rb [29]. Transduction of 97-7 with shBMI1-A or
shBMI1-B resulted in 37% or 88% decreases in BMI1 transcript
level, respectively. 97-7 siRNA B therefore had BMI1 levels reduced to
slightly less than the endogenous level detectable in pooled NHUC.
Knockdown of BMI1 repressed adhesion in 97-7 (Figure 4D) in
contrast to the trend in increased adhesion seen with overexpression
in NHUC.
Discussion
Overexpression of BMI1 is reported in many cancer types [30–33],
and in some, its expression correlates with clinicopathological
parameters [34–37]. However, its role in urothelial tumorigenesis
has not been clearly defined, and conflicting data have arisen from
existing studies. Following careful validation of IHC staining, we
found nuclear overexpression of BMI1 in the majority of UC. Unlike
previous studies [30,38], these IHC results were confirmed in a
second independent tumor panel. There was no correlation of BMI1
protein expression with the stage or grade of the tumor, supporting
our observation of no association of BMI1 transcript level with tumor
stage or grade. Since our study was initiated, Liang et al. used the same
BMI1 antibody, a smaller UC panel of differing stage and gradedistribution, and a different scoring system to investigate BMI1
expression in UC. In contrast to our results, an association of BMI1
expression with tumor stage and grade was reported [12]. To account
for the effect of different scoring classification, we also performed
statistical analysis using criteria equivalent to Liang et al. (grouping
tumors as Ta, T1, and T2+ and staining of 0 or 1 vs 2 and 3). Still, we
found no association of BMI1 expression with stage or grade, as was
expected from the overall low frequency of BMI1-negative/low
tumors in our panel.
Although extremely frequent, overexpression of BMI1 was not a
ubiquitous event in UC. It is known that BMI1-negative tumors are a
distinct subpopulation in Ewing’s sarcoma, with a distinct gene
expression profile [39]. Only eight UCs in our original tumor panel
and only five in the second TMA panel were BMI1 negative. The
small numbers of tumors studied here make interpretation
impossible, but it is conceivable that BMI1-negative tumors follow
a distinct PRC1-independent pathway to tumorigenesis, and this is a
subject worthy of further investigation.
In hematological malignancy, BMI1 is targeted by chromosomal
rearrangements [40], but in solid epithelial cancers, there is no evidence
to support this. The 10p11.23 region is not a common site of
amplification in UC [41], and accordingly, correlation between BMI1
copy number and overexpression in UC cell lines was not observed.
Figure 4. (A) BMI1-associated changes in gene expression could affect pathways relevant to cellular adhesion. Blue thermometers
indicate a downregulation of gene expression in NHUC-BMI1 (relative to NHUC); and red thermometers, overexpression. (B) A trend of
increased adhesion was seen in NHUC ectopically overexpressing BMI1 from three donors compared with NHUC. (C) Overexpression of
BMI1 increased Transwell migration of NHUC from three of three donors investigated. Data are representative of three or two
independent experiments. Errors bars show plus and minus standard deviation of triplicates repeats within each experiment. *P b .05,
unpaired t test. (D) Knockdown of BMI1 repressed adhesion in 97-7, UC cell line.
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mortalized normal human urothelial cells during experiments aimed
at modeling the early steps in bladder tumor development [6]. Our
results indicate that upregulation of BMI1 is an early event in UC
development. We consider that, in bladder cancer patients, the entire
urothelium is altered because of the spread of tumor and
premalignant cells. Initiation of MIBC arises from a CIS precursor
lesion which expands to colonize the urothelium [42]. BMI1
expression was examined in a pilot study of premalignant bladder
lesions including CIS. BMI1 was upregulated in a subset. Previous
studies also support the notion of upregulation of BMI1 in potentiallypremalignant urothelium. Shafaroudi et al. describe 25% of tumor
margins exhibiting expression of BMI1 transcript [38], and Qin et al.
demonstrated upregulation of BMI1 transcript in adjacent “normal”
tissue in bladder cancer patients [30]. The concept of a role for BMI1
in early tumorigenesis is not unprecedented because upregulation is
reported in other epithelial premalignancies such as colorectal, lung,
oral tissue, and esophageal tissue [43–45]. As is expected for an early
event, in some of the associated tumor types, such as esophageal
carcinoma, no association is seen between BMI1 overexpression and
subsequent tumor stage or grade [46]. In parallel to our results, in oral
tissue, BMI1 is upregulated at a very early stage in oral tumorigenesis
Table 4. Analysis of NHUC-BMI1 Gene List by Protein Function
# Pathway Maps Total P Value Min FDR P Value FDR In
Data
Network Objects from NHUC-BMI1 Data
1 Cytoskeleton remodeling_Role of PKA in
cytoskeleton reorganization
40 9.613E-06 3.711E-03 9.613E-06 3.711E-03 8 ROCK, MLCK, PKA-cat (cAMP-dependent), G-protein alpha-s, Calmodulin,
BETA-PIX, MLCP (reg), MLCP (cat)
2 Apoptosis and
survival_BAD phosphorylation
42 1.408E-05 3.711E-03 1.408E-05 3.711E-03 8 PKA-cat (cAMP-dependent), JNK1(MAPK8), PI3K cat class IA, G-protein alpha-s,
p90Rsk, PP2C, IRS-1, Cytochrome c
3 Development_A2A receptor signaling 43 1.689E-05 3.711E-03 1.689E-05 3.711E-03 8 CREB1, PDZ-GEF1, PKA-cat (cAMP-dependent), JNK(MAPK8-10), PI3K cat
class IA, G-protein alpha-s, p90Rsk, BETA-PIX
4 Transcription_CREB pathway 49 4.563E-05 5.979E-03 4.563E-05 5.979E-03 8 CREB1, PKA-cat (cAMP-dependent), PI3K cat class IA, G-protein alpha-s,
Calmodulin, p90Rsk, IRS-1, PP1-cat
5 Signal transduction_cAMP signaling 38 6.170E-05 5.979E-03 6.170E-05 5.979E-03 7 GSK3 alpha/beta, RAP-2A, CREB1, PKA-cat (cAMP-dependent), G-protein
alpha-s, PKC, Calmodulin
6 Translation_Regulation of translation
initiation
27 6.940E-05 5.979E-03 6.940E-05 5.979E-03 6 eIF4A, eIF1, eIF3S8, eIF5, eIF1A, eIF5B (IF-2)
7 Signal transduction_Activation of PKC via
G-Protein coupled receptor
52 7.098E-05 5.979E-03 7.098E-05 5.979E-03 8 GSK3 be ta , MLCK, PKC- l ambda/ io t a , Ca lmodu l in , PKC-mu,
NF-AT2(NFATC1), MLCP (reg), MLCP (cat)
8 Translation _Regulation of EIF2 activity 39 7.348E-05 5.979E-03 7.348E-05 5.979E-03 7 GSK3 alpha/beta, PI3K cat class IA, Casein kinase I, DYRK2, IRS-1, PKR, PP1-cat
9 Cell cycle_Influence of Ras and Rho
proteins on G1/S Transition
53 8.166E-05 5.979E-03 8.166E-05 5.979E-03 8 GSK3 beta, ROCK2, MLCK, JNK1(MAPK8), PI3K cat class IA, CDK6, MLCP
(reg), MLCP (cat)
10 Cytoskeleton remodeling_Cytoskeleton
remodeling
102 9.588E-05 6.318E-03 9.588E-05 6.318E-03 11 eIF4A, GSK3 beta, ROCK, ROCK2, MYLK1, MLCK, PI3K cat class IA, TGF-beta
receptor type I, PTEN, MLCP (reg), MLCP (cat)
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suggested by Kang et al., the detection of BMI1 has potential for use
in the identification of potentially premalignant lesions. Of note, in
our study, the patient from whom the check cystoscopy biopsy that
was classified as “no evidence of malignancy” by standard histological
analysis and showed strong nuclear BMI1 upregulation was derived
went on to develop fatal metastatic UC. Whether upregulation of
BMI1 in potentially premalignant lesions is predictive of outcome is
currently unknown, but further investigation of the significance of
detection of BMI1 is planned.
BMI1 is commonly cited as being a transcriptional repressor of
the CDKN2A locus. The promoter of p16 contains a BMI1
responding unit, and BMI1 and p16 expression correlate in some
tumor types [28]. We have previously shown that, in UC,
downregulation of p16 expression is most often associated with
homozygous deletion or loss of heterozygosity of the 9p21 region,
and it is this rather than transcriptional repression which may be
key in determining the p16 level [17]. Indeed, in the whole
tumor section panel, 28 UCs exhibited strong expression of both
BMI1 and p16, and coexpression was confirmed in the second
TMA panel.
Having established upregulation of BMI1 as a frequent and
potentially early event in bladder cancer, we set out to investigate the
phenotypic significance of its overexpression in NHUC. In vitro,
overexpression of BMI1 induced telomerase activity (as is reported
for mammary epithelial cells [49]) and immortalized NHUC without
the need for silencing of p16. Similarly, in Ewing’s sarcoma, the
actions of BMI1 are independent of repression of p16 expression [10].
Overexpression of BMI1 alone also immortalizes nasopharyngeal
epithelial cells [47], whereas in other human cell types, expression of
hTERT [48] or prior silencing of p16 is also required [49]. The fact
that BMI1 and hTERT are required for immortalization of some cell
types such as gingival keratinocytes [50] indicates that the role of
BMI1 in tumorigenesis is greater than merely induction of telomerase
activity and its subsequent downstream effects. In UC, it appears
that the functions of BMI1 in tumorigenesis also extend beyond
suppression of the CDKN2A locus.
Gene expression analysis of NHUC-BMI1 was performed to
investigate the potential transcriptional effects of BMI1 in urothelialtumorigenesis. A profile of genes consistently altered in BMI1-
transduced cells was obtained. The NHUC-BMI1 gene list was
subjected to Metacore analyses. The most significant process network
affected was transcription and mRNA processing, supporting the
wealth of existing literature describing BMI1 as a key molecule in
control of downstream gene expression. Chromatin remodeling genes
have been shown to be frequent targets of mutation in UC [51].
Notably, downregulation of transcripts for chromodomain-helicase
DNA binding protein 1 (CHD1), CHD1L, CHD2, CHD7, and
CHD9 was observed. CHD2 is proposed as a tumor suppressor gene
that regulates DNA damage response [52]. Interestingly, TCGA data
show that 9% of bladder carcinomas exhibit mutation in this gene
(www.cbioportal.org).
The key pathway map enriched in NHUC-BMI1 expression
profile was “cytoskeleton remodeling_Role of PKA in cytoskeleton
reorganisation”. Epithelial–mesenchymal transition is a multistep
process by which epithelial cells acquire migratory and invasive
properties, and in some cell types, activation of BMI1 is required for
epithelial–mesenchymal transition [53]. The ability of mesenchymal-
like migration, as observed in cancer cells, relies on an intricate
balance between adhesion assembly and disassembly. Overexpression
of BMI1 led to downregulation of PKA-cat. This molecule is
responsible for the phosphorylation and deactivation of α4/β1
integrin, a key molecule in cell adhesion. The resulting BMI1-
transduced cells had increased adhesion coupled to enhanced cellular
migration. Our results support the recent report that knockdown of
BMI1 in the T24 UC cell line inhibits invasion in vitro[12] and may
represent an action of BMI1 that is more relevant to the later stages of
cancer development.
Using Metacore, data were analyzed to identify interactions of the
BMI1-associated changes in gene expression by protein function.
YY1, a transcription factor and key component of the polycomb
initiation complex PRC2, was the most significant network object. In
concordance with published literature, genes that interacted with
c-Myc, p53, and ESR1 were overrepresented. However, a novel
finding was that genes that were targets of cyclic AMP-responsive
element binding protein 1 (CREB1) were highly overrepresented and
both CREB1 and its target genes were downregulated in
NHUC-BMI1. The CREB signaling pathway potentially modulates
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through cAMP-induced phospohorylation, and NHUC-BMI1 had
upregulation of p90RSK kinase, a known CREB1 activator.
Having identified a “profile” of BMI1-associated changes in gene
expression in NHUC, we compared this with other BMI1-associated
signatures in other cell types and contexts. An 11-gene BMI1 pathway
gene signature has been identified in metastatic prostate cancer and
neural stem cells and is predictive of poor outcome in multiple tumor
types including bladder [55]. We found that only one of these
signature genes, encoding the ankyrin protein (ANK3), was also
altered in NHUC-BMI1. The NHUC-BMI1 gene expression profile
did show downregulation of 3 of the 11 previously identified
telomerase “signature genes” [6] in NHUC (TSPYL5, NME5,
CEACAM6) and the putative tumor suppressor gene NDN [14],
suggesting cell type– and cell context–specific effects. In particular,
loss of CEACAM6 (CD66c) expression has been associated with the
so-called “highly tumorigenic basal cell compartment” of UC, which
is believed to exhibit stem cell–like properties [56]. CEACAM6 was
downregulated in both TERT-NHUC [6] and NHUC-BMI1,
suggesting that, to some extent, these immortal cell lines resemble
“stem cell–like” cells. BMI1 is overexpressed in human bladder cancer
stem cell–like populations. In these cells, knockdown of BMI1
inhibited proliferation, migration, and tumor sphere formation;
increased cisplatin sensitivity; and is essential for their tumorigenicity
in mouse models [57].
BMI1 is a target for the development of novel small molecule
inhibitors [58] and also a transcriptional target of histone deacetylase
inhibitor drugs [59]. BMI1-null mice gradually succumb because of a
progressive neurological and hematopoietic dysfunction [60] pre-
sumably due to stem cell dysfunction. As with many conventional
cancer treatments, it would be expected that a BMI1 inhibitor would
be toxic to normal human adult stem cells in addition to targeting
tumor cells. However, an increased knowledge of the downstream
effects of BMI1 on gene expression may aid the development of
alternative strategies with a lower toxicity or indicate ways to
ameliorate the side effects of BMI1 inhibition. If overexpression of
BMI1 is a key feature of CIS, identification of BMI1-associated
changes in gene expression could point toward pathways that could be
targeted in this highly clinically relevant subpopulation.
Conclusion
BMI1 has many p16-independent actions that may contribute to
neoplasia. As a key modulator of gene expression, cellular phenotype,
and keystone signaling pathways, BMI1 is worthy of future
investigation as a therapeutic target in UC. Future studies are
required to confirm of the role of BMI1 in α4/β1 integrin-mediated
adhesion, kinase-mediated changes in cytoskeleton, and CREB-1
transcriptional regulation in cancer. Further analysis of BMI1
expression in premalignant bladder lesions and its correlation with
outcome and expression in subsequent tumors is merited.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.08.002.
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